Authors
Matthew B Nodelman, Morgan Adams Rhodes, Charles Carter
Published in
American family physician. Volume 114. Issue 5. Pages 484-495.
Abstract
Hyperlipidemia management is key to overall cardiovascular risk reduction. Validated risk calculators, including the updated PREVENT (Predicting Risk of Cardiovascular Disease Events) equation and Pooled Cohort Equations, should be used to guide lipid-lowering therapy in adults without known atherosclerotic cardiovascular disease (ASCVD). Lipid-lowering medications have shown benefit for primary and secondary prevention of ASCVD, supported by guidelines from the American College of Cardiology/American Heart Association, US Department of Veterans Affairs/US Department of Defense, and the National Institute for Health and Care Excellence. Statins remain first-line agents for primary and secondary prevention, with consistent evidence demonstrating reductions in major adverse cardiovascular events, myocardial infarction, stroke, and all-cause mortality. Statin therapy is recommended for primary prevention in adults 40 to 75 years of age with diabetes, chronic kidney disease stage 3 or higher, or HIV; in patients with low-density lipoprotein cholesterol levels of 190 mg/dL or greater; and in those with elevated 10-year ASCVD risk. Current American College of Cardiology/American Heart Association guidelines expand the recommendation to 30 to 79 years of age. Nonstatin therapies should be considered in patients who cannot tolerate statins or do not achieve adequate low-density lipoprotein cholesterol reduction. Adjunctive therapies may be appropriate for secondary prevention in certain patients. Older adults, younger adults with elevated lifetime risk, and patients of childbearing potential require special considerations. Lipid-lowering therapy should be individualized based on risk assessment, guideline thresholds, and shared decision-making.
PMID:
43062880
Bibliographic data and abstract were imported from PubMed on 21 Nov 2026.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0